Arindam Ganguly

Arindam Ganguly is an accomplished professional with extensive experience in the pharmaceutical and healthcare sectors. Currently serving as Director of US CVRM Forecasting for Baxdrostat at AstraZeneca and Director of Global Commercial Assessment & Strategic Forecasting for Keytruda at Merck, Arindam leads strategic forecasting efforts for key oncology products. Previous roles include Strategy, Insights and Planning Consultant at ZS, Financial Planning & Analysis lead for the Cardiovascular Franchise at Novartis, and Senior Associate at BR Venture Fund. Arindam has demonstrated expertise in financial analysis, market research, drug development processes, and cross-functional collaboration, with a strong academic background including an MBA from Cornell University and a Ph.D. in Chemistry from the University of Missouri-Kansas City.